---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005406"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:44:07.567301+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences Q2 2025 net loss $44.2M, including $31.25M litigation reserve; shifts focus to TSC epilepsy

## Summary
- Net loss $44.2M ($0.92 per share) vs net income $6.2M in Q2 2024.
- Recorded $31.25M estimated loss contingency for securities litigation settlement.
- Alzheimer's program phased out; new focus on simufilam for TSC-related epilepsy - PoC study expected H1 2026.
- Cash $112.4M at June 30, 2025; H2 2025 net cash use $47-51M including litigation reserve.
- Appointed Dr. Hulihan (CMO), Dr. Bordey (SVP Neuroscience), Dr. Moore (SVP Clin Dev).

## SEC filing metadata
- accession: 0001171843-25-005406
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/0001171843-25-005406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/f8k_081425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005406
- JSON: https://secwatch.observer/filing/0001171843-25-005406.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.